抗癌祛毒方对中晚期宫颈癌患者肿瘤标志物、免疫功能影响及机制探讨  

Effect and Mechanism of Kang'ai Qudu Recipe(抗癌祛毒方)on Tumor Markers and Immune Function in Patients with Advanced Cervical Cancer

作　　者：陈娟 朱凤婷 冯冬婵 麦丽珍[1] CHEN Juan;ZHU Fengting;FENG Dongchan;MAI Lizhen(Hainan Traditional Chinese Medicine Hospital,Haikou 570203,Hainan,China)

机构地区：[1]海南省中医院,海南海口570203

出　　处：《中华中医药学刊》2023年第8期89-92,共4页Chinese Archives of Traditional Chinese Medicine

基　　金：国家自然科学基金项目(81660823);海南省卫生计生行业科研项目(16A200006)。

摘　　要：目的观察抗癌祛毒方联合新辅助化疗治疗中晚期宫颈癌患者的临床疗效及其对肿瘤标志物和免疫功能的影响。方法选取2019年2月-2021年1月海南省中医院收治的45例中晚期宫颈癌患者,随机分为两组,其中对照组予以新辅助化疗方案,中药组予以新辅助化疗联合抗癌祛毒方。比较两组治疗后的临床疗效,以及药物干预后免疫功能和血清肿瘤标志物水平变化。结果对照组客观缓解(Overall response rate,ORR)为54.55%(12/22),中药组ORR为82.16%(19/23),中药组的ORR显著上调(P<0.05)。经治疗,中药组病人血清中细胞角蛋白19片段抗原(Cytokeratin 19 fragment antigen 21-1,CYFRA21-1)、糖类抗原125(Carbohydrate antigen,CA125)、鳞状上皮细胞癌抗原(Squamous cell carcinoma antigen,SCC-Ag)以及癌胚抗原(Carcino-embryonic antigen,CEA)水平相较于对照组明显下调(P<0.01);与对照组比较,中药组CD_(8)^(+)水平明显下调,而CD_(4)^(+)/CD_(8)^(+)、CD_(3)^(+)和CD_(4)^(+)水平上升(P<0.01,P<0.05)。对照组随访半年局部复发和远处转移患者分别为6、3例,中药组随访半年局部复发和远处转移患者分别为2、1例,中药组的肿瘤转移总发生率(13.04%,3/23)较对照组(40.91%,9/22)明显下调(P<0.05)。两组病人治疗过程中生命体征平稳,与对照组比较,中药组的不良反应无明显增加,差异不具有统计学意义(P>0.05)。结论新辅助化疗联合抗癌祛毒方可提高治疗中晚期宫颈癌的短期临床疗效,抑制肿瘤转移,其机制与调节病人免疫功能及抑制炎症反应有关。Objective To observe The effect and mechanism of Kang'ai Qudu Recipe(抗癌祛毒方) on tumor markers and immune function in patients with advanced cervical cancer. Methods Forty-five patients with advanced cervical cancer treated in Hainan Traditional Chinese Medicine Hospital from February 2019 to January 2021 were randomly divided into two groups. The patients in the control group were given neoadjuvant chefmotherapy, and those in the traditional Chinese medicine group were given neoadjuvant chemotherapy combined with Kang'ai Qudu Recipe. The clinical efficacy and the changes of serum tumor markers and immune function before and after treatment were compared between the two groups. Results The overall response rate(ORR) was 54.55%(12/22) in the control group and 82.16%(19/23) in the traditional Chinese medicine group, and the ORR was significantly up-regulated in the traditional Chinese medicine group(P<0.05). After treatment, cytokeratin 19 fragment antigen 21-1(CYFRA21-1),carbohydrate antigen 125(CA125),squamous cell carcinoma antigen(SCC-AG) and carcino-embryonic antigen(CEA) in the traditional Chinese medicine group. were significantly down-regulated compared with those of the control group(P<0.01). Compared with those of the control group, the level of CD_(8)^(+) in the traditional Chinese medicine group was significantly down-regulated, while the levels of CD_(4)^(+)/CD_(8)^(+),CD_(3)^(+) and CD_(4)^(+) were increased(P<0.01,P<0.05). There were 6 and 3 cases of local recurrence and distant metastasis in the control group and 2 and 1 cases of local recurrence and distant metastasis in the traditional Chinese medicine group, respectively. The total incidence of tumor metastasis in the traditional Chinese medicine group(13.04%,3/23) was significantly lower than that in the control group(40.91%,9/22)(P<0.05). The vital signs of patients in the two groups were stable during treatment. Compared with those of the control group, the adverse reactions in the traditional Chinese medicine group were not increase s

关 键 词：中晚期宫颈癌 抗癌祛毒方 新辅助化疗 临床疗效 免疫功能 

分 类 号：R737.33[医药卫生—肿瘤]